Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06510491 · ClinicalTrials.gov registry record · Phase 2
Epcoritamab in Previously Treated WM
A Phase 2 study of Waldenstrom Macroglobulinemia and B-Cell Lymphoproliferative Disorder, sponsored by Gottfried von Keudell, MD PhD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT06510491 is a Phase 2 study of Waldenstrom Macroglobulinemia and B-Cell Lymphoproliferative Disorder that is actively recruiting participants, run by Gottfried von Keudell, MD PhD. The registered enrollment target is 20 participants, below the 473-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT06510491, a Phase 2 study of Waldenstrom Macroglobulinemia and B-Cell Lymphoproliferative Disorder, is actively recruiting participants, sponsored by Gottfried von Keudell, MD PhD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is being done to determine if epcoritamab can be used to treat participants with previously treated Waldenstrom Macroglobulinemia (WM). The names of the study drug involved in this study is: -Epcoritamab (a type of antibody)
Conditions Studied
Interventions
- DRUG Epcoritamab
Study Locations (3)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-12-06 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06510491
The ClinicalTrials.gov registry entry for NCT06510491 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 473-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (96% lower). The listed sponsor is Gottfried von Keudell, MD PhD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Waldenstrom Macroglobulinemia appearing as the primary indexed condition, and to 1 intervention - of which Epcoritamab is the first listed.
NCT06510491 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06510491 about?
NCT06510491 is a clinical study titled "Epcoritamab in Previously Treated WM". This study is being done to determine if epcoritamab can be used to treat participants with previously treated Waldenstrom Macroglobulinemia (WM). The names of the study drug involved in this study is: -Epcoritamab (a type of antibody)
What is the current status of trial NCT06510491?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-12-06. Estimated completion is 2027-12-31.
What conditions does trial NCT06510491 study?
This clinical trial studies the following conditions: Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder.
What interventions are being tested in trial NCT06510491?
The interventions under investigation include: Epcoritamab (DRUG).
Who is sponsoring clinical trial NCT06510491?
This trial is sponsored by Gottfried von Keudell, MD PhD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06510491 being conducted?
This trial has 3 study locations across Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Waldenstrom Macroglobulinemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
RECRUITING · Phase 2
-
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
RECRUITING · Phase 2
-
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
RECRUITING · Phase 2
-
Loncastuximab Tesirine in WM
RECRUITING · Phase 2
-
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
RECRUITING · Phase 2
-
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Waldenstrom Macroglobulinemia
All registered trials for this condition
B-Cell Lymphoproliferative Disorder
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.